New oral anticoagulants and cardiac safety: do we have a problem?

Abstract

This analytic review provides the information about frequency of myocardial infarction in patients, treated with direct oral anticoagulants in randomized clinical trials and retrospective cohort studies. It is indicated that direct thrombin inhibitor dabigatran has higher incidence of myocardial infarctions than warfarin. Direct factor Xa inhibitor rivaroxaban has the most convincing arguments of coronary safety.

Keywords

• apixaban
• dabigatran
• rivaroxaban
• myocardial infarction